Sinphar Pharmaceutical Co (TPE:1734) ROCE %: 8.98% (As of Dec. 2025)


TPE:1734 Sinphar Pharmaceutical Co Ltd TPE:1734
81 GF Score
Price NT$32.00
GF Value NT$33.13
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Sinphar Pharmaceutical Co ROCE %?

Sinphar Pharmaceutical Co TPE:1734 -1.08% 81 ROCE % is 8.98% as of Dec. 2025. GuruFocus rates TPE:1734 with a GF Score™ of 81/100 and a GF Value™ of NT$33.13 (Fairly Valued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sinphar Pharmaceutical Co's annualized ROCE % for the quarter that ended in Dec. 2025 was 8.98%.

Sinphar Pharmaceutical Co  (TPE:1734) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sinphar Pharmaceutical Co ROCE % Related Terms

Sinphar Pharmaceutical Co ROCE % Historical Data

* Premium members only.

The historical data trend for Sinphar Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinphar Pharmaceutical Co ROCE % Chart

Sinphar Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.37 5.79 6.94 6.93 8.69

Sinphar Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.05 9.39 7.04 9.19 8.98
TPE:1734
81GF Score
Sinphar Pharmaceutical Co Ltd TPE:1734
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinphar Pharmaceutical Co ROCE % Calculation

Sinphar Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=435.371/( ( (6298.255 - 1422.809) + (6153.05 - 1011.481) )/ 2 )
=435.371/( (4875.446+5141.569)/ 2 )
=435.371/5008.5075
=8.69 %

Sinphar Pharmaceutical Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=454.596/( ( (6126.123 - 1143.425) + (6153.05 - 1011.481) )/ 2 )
=454.596/( ( 4982.698 + 5141.569 )/ 2 )
=454.596/5062.1335
=8.98 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 8.98% mean?
Sinphar Pharmaceutical Co (TPE:1734) has a ROCE % of 8.98% as of Dec. 2025.
Is Sinphar Pharmaceutical Co's ROCE % too high?
Sinphar Pharmaceutical Co's current ROCE % is 8.98%. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's ROCE % compare to VRTX and REGN?
Sinphar Pharmaceutical Co's ROCE % of 8.98% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Sinphar Pharmaceutical Co's current ROCE % is 8.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.13, compared to a current price of NT$32.00 — trading 3.4% below its estimated fair value. The current ROCE % is 8.98%. Sinphar Pharmaceutical Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current ROCE % is 8.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?

Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$32.00 is trading 3.4% below its estimated GF Value™ of NT$33.13. GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TPE:1734:

  • ROCE %: 8.98%
  • GF Value™: NT$33.13 vs. price of NT$32.00 (3.4% below fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinphar Pharmaceutical Co Business Description

Address No.84, Zhongshan Road, Dongshan Township, Zhongshan Village, Yilan, TWN, 269
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
81GF Score

Get the complete analysis for TPE:1734

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.00
Price
NT$33.13
GF Value